Neuronetics (STIM) to Release Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) will be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Neuronetics to post earnings of ($0.33) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. The firm had revenue of $20.31 million during the quarter, compared to analyst estimates of $19.73 million. During the same period last year, the company posted ($0.30) EPS. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Price Performance

Shares of STIM opened at $3.81 on Friday. The business’s 50-day moving average is $3.96 and its 200-day moving average is $2.91. The company has a debt-to-equity ratio of 1.73, a current ratio of 4.73 and a quick ratio of 4.33. The company has a market capitalization of $114.20 million, a price-to-earnings ratio of -3.56 and a beta of 2.50. Neuronetics has a fifty-two week low of $1.03 and a fifty-two week high of $5.07.

Wall Street Analyst Weigh In

STIM has been the subject of a number of research reports. William Blair reissued a “market perform” rating on shares of Neuronetics in a research note on Tuesday, March 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $8.00 target price (up from $7.00) on shares of Neuronetics in a research report on Wednesday, March 6th.

Insider Buying and Selling

In other Neuronetics news, EVP William Andrew Macan sold 15,621 shares of Neuronetics stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $3.38, for a total value of $52,798.98. Following the transaction, the executive vice president now directly owns 417,736 shares of the company’s stock, valued at approximately $1,411,947.68. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Neuronetics news, EVP William Andrew Macan sold 15,621 shares of the firm’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $3.38, for a total value of $52,798.98. Following the sale, the executive vice president now directly owns 417,736 shares in the company, valued at approximately $1,411,947.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Furlong sold 14,710 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $3.51, for a total transaction of $51,632.10. Following the transaction, the chief financial officer now directly owns 509,033 shares of the company’s stock, valued at approximately $1,786,705.83. The disclosure for this sale can be found here. In the last 90 days, insiders sold 150,279 shares of company stock valued at $489,167. Insiders own 9.80% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.